
News|Articles|June 1, 2002
Part 2: Beyond depression: Evaluation of newer indications and off-label uses for SSRIs (PDF)
In this final installment of this series, the authors focus on the use of SSRIs in alcohol dependence, chronic pain, eating disorders, premenstrual dysphoric disorder, and sexual dysfunction. For each condition, the authors examine how well clinical trial evidence supports the application, discuss dosing and safety considerations, and provide their recommendations on preferred and alternative SSRIs, based on the weight of the evidence.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Schizophrenia, Bipolar Disorder, and MDD Linked to Increased Risk for Developing Long COVID
2
MHE Week in Review – White House GLP-1 Deal, AI Spots Cancer Risk and More
3
Health Plans Beware: Keep Contract Language Tight If Your PBM Wants Rebate Guarantees Renegotiated Because of the IRA and Biosimilars | AMCP Nexus 2025
4
PBMs Make a Case for the GLP-1 Teeter Totter: Up on the Pharmacy Benefit, Down on the Medical One | AMCP Nexus 2025
5

















































